.jpg?20201202')
The head of the European Union's medicines agency Guido Rasi said on Monday an initial authorisation for U.S. pharmaceutical company Gilead's remdesivir as a COVID-19 treatment could be granted in coming days.
"It might be that a conditional market authorisation can be issued in the coming days," Rasi told a hearing in the EU Parliament in Brussels.
The European Medicines Agency (EMA) has already recommended the compassionate use of remdesivir, which allows a drug to be administered to patients even before it has been fully authorised.